A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas

Background. Belinostat is a novel histone deacetylase inhibitor. Primary Objectives. Maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of belinostat (Bel) in combination with doxorubicin (Dox) in solid tumours (phase I) and response rate (RR) in soft tissue sarcomas (phase II). Method...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sarcoma
Main Authors: Vitfell-Rasmussen, Joanna, Judson, Ian, Safwat, Akmal, Jones, Robin L., Rossen, Philip Blach, Lind-Hansen, Maja, Knoblauch, Poul, Krarup-Hansen, Anders
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2016
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4923583/
https://ncbi.nlm.nih.gov/pubmed/27403082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/2090271
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados